Published :
Tables : 65
Figures : 55
Category : Healthcare
No. of Pages : 240
Report Code : HC-U3320
Mucopolysaccharidosis Market is estimated to value over USD 4 billion by 2027 end with a CAGR of over 10.2% during the forecast period 2020 to 2027. Mucopolysaccharidosis, or MPS, are a group of rare metabolic disorders that are caused by the absence of lysosomal or malfunctioning enzymes known as glycosaminoglycan. This disorder creates an inability of breaking down sugars in the body, resulting in the over accumulation of compounds like heparan sulphate, keratan sulphate and dermatan sulphate that interferes the normal functioning of body cells. Severe neurological symptoms like Sanfilippo syndrome and hunter syndrome are some of the primary symptoms of mucopolysaccharidosis and key players are involved in the research and development of advanced therapeutics for managing these symptoms. Rising number of candidates from such key players in rare disease therapeutics sector shall boost the mucopolysaccharidosis market growth. This is mainly because it is easy to develop major drugs for rare diseases in comparison with other pharma portfolios and it is also mandatory for pharmaceutical companies to conduct studies with large scale results for traditional therapies and medications as compared to the therapies required for rare diseases. Furthermore, the rare diseases like MPS have a limited number of therapies like the enzyme replacement therapy for treating MPS II or hunter syndrome and this monopoly shall propel the proliferation of the market. However, some of the therapies like Vimizim, which is used for treating MPS IV A, costs over USD 380,000 which is expensive for patients from developing nations like China. Additionally, some of these therapies are unable to identify the neurological symptoms and other complications present in MPS patients. For instance, therapeutics like Aldurazyme and Elaprase are unable to cross the brain-blood barrier which is essential for managing the disorder effectively. Such factors shall encourage companies for conducting extensive researches in developing advanced therapeutic measures that can identify these neurological symptoms in earlier stages and manage the disorder. There has been a substantial rise in the number of patients diagnosed with MPS. As per the data provided by the National Organization for Rare Disorders, the occurrence of all types of MPS is predicted to be one in over 24,000 births. It was reported in April 2019 that over 140 individuals in Japan were diagnosed with MPS type II (Hunter Syndrome). Such a rise shall bolster the augmentation of the market. However, the high prevalence of MPS in countries where patients are unable to afford the therapeutic treatments shall restrain the growth of the market. A substantial proportion of MPS patients could not undergo treatment owing to their financial conditions and to add to that, people in developing countries are unaware about treatment alternatives for rare disease like MPS and the healthcare insurance policies do not cover such rare diseases in their reimbursements which further limits the number of patients opting for these therapies. As per a study conducted by the Orphanet Journal of Rare Diseases, in case of MPS type I and MPS type III, there has been a massive failure in reducing the diagnostic gap in these diseases and reasons like these shall substantially impede the market growth. Market Segmentation: By Treatment • Enzyme Replacement Therapy • Others By Disease Type • Mucopolysaccharidosis Type I • Mucopolysaccharidosis Type II • Mucopolysaccharidosis Type IV A • Mucopolysaccharidosis Type VI • Others By Route of Administration • Intravenous • Intracerebroventricular By End User • Hospitals • Specialty Clinics • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is classified into treatment, disease type, route of administration, end user and region. The treatment segment is divided into enzyme replacement therapy and others. The enzyme replacement therapy is the primary treatment for MPS disorders, and they aim at replacing or generating the enzymes that are missing in the body, which is the primary reason for causing MPS. ERTs are the only approves therapeutics for MPS like for instance, MPS type II treatment has two therapeutics options, Hunterase and Elaprase, both of which are enzyme replacement therapies. Such a monopoly shall let this segment dominate the market during the forecast period. Other treatments such as hematopoietic stem cell transplants are under clinical trials which once approved, shall increase its demand amongst patients, thereby boosting its growth during the forecast period. The disease type segment is categorised into mucopolysaccharidosis type I, mucopolysaccharidosis type II, mucopolysaccharidosis IV A, mucopolysaccharidosis VI and others. The mucopolysaccharidosis type II or Hunter syndrome, is predicted to lead the market growth during the forecast period owing to the rising number of MPS type II patients across the world along with the availability of Elaprase and Hunterase. The route of administration segment is fragmented into intravenous and intracerebroventricular. The intravenous segment is predicted to hold the mucopolysaccharidosis market share as MPS therapies like Elaprase are administered with the help of intravenous injections. The end user segment is bifurcated into specialty clinics, hospitals and others. The hospitals segment is poised to dominate the market, and this can be credited to the availability of trained healthcare professionals who can administer these therapies in hospital settings. Regional Analysis: The North America region is expected to dominate the market owing to the increased rate of treatment of rare diseases and the higher rate of rare disease diagnosis in the region. Furthermore, there has been significant improvements in the reimbursement policies for these therapies couple with a rising awareness amongst patients regarding the treatment of MPS. Additionally, a strong presence of key market players in the region who are constantly looking for alternate cost-effective therapies which shall bolster the market domination. Competitive Landscape: Some of the key players are Shire (Takeda Pharmaceutical Co. Ltd.), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, Genzyme Corp. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global mucopolysaccharidosis market by treatment, by disease type, by route of administration, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Mucopolysaccharidosis, or MPS, are a group of rare metabolic disorders that are caused by the absence of lysosomal or malfunctioning enzymes known as glycosaminoglycan. This disorder creates an inability of breaking down sugars in the body, resulting in the over accumulation of compounds like heparan sulphate, keratan sulphate and dermatan sulphate that interferes the normal functioning of body cells. Severe neurological symptoms like Sanfilippo syndrome and hunter syndrome are some of the primary symptoms of mucopolysaccharidosis and key players are involved in the research and development of advanced therapeutics for managing these symptoms. Rising number of candidates from such key players in rare disease therapeutics sector shall boost the mucopolysaccharidosis market growth. This is mainly because it is easy to develop major drugs for rare diseases in comparison with other pharma portfolios and it is also mandatory for pharmaceutical companies to conduct studies with large scale results for traditional therapies and medications as compared to the therapies required for rare diseases. Furthermore, the rare diseases like MPS have a limited number of therapies like the enzyme replacement therapy for treating MPS II or hunter syndrome and this monopoly shall propel the proliferation of the market. However, some of the therapies like Vimizim, which is used for treating MPS IV A, costs over USD 380,000 which is expensive for patients from developing nations like China. Additionally, some of these therapies are unable to identify the neurological symptoms and other complications present in MPS patients. For instance, therapeutics like Aldurazyme and Elaprase are unable to cross the brain-blood barrier which is essential for managing the disorder effectively. Such factors shall encourage companies for conducting extensive researches in developing advanced therapeutic measures that can identify these neurological symptoms in earlier stages and manage the disorder. There has been a substantial rise in the number of patients diagnosed with MPS. As per the data provided by the National Organization for Rare Disorders, the occurrence of all types of MPS is predicted to be one in over 24,000 births. It was reported in April 2019 that over 140 individuals in Japan were diagnosed with MPS type II (Hunter Syndrome). Such a rise shall bolster the augmentation of the market. However, the high prevalence of MPS in countries where patients are unable to afford the therapeutic treatments shall restrain the growth of the market. A substantial proportion of MPS patients could not undergo treatment owing to their financial conditions and to add to that, people in developing countries are unaware about treatment alternatives for rare disease like MPS and the healthcare insurance policies do not cover such rare diseases in their reimbursements which further limits the number of patients opting for these therapies. As per a study conducted by the Orphanet Journal of Rare Diseases, in case of MPS type I and MPS type III, there has been a massive failure in reducing the diagnostic gap in these diseases and reasons like these shall substantially impede the market growth.
Market Segmentation:
By Treatment • Enzyme Replacement Therapy • Others By Disease Type • Mucopolysaccharidosis Type I • Mucopolysaccharidosis Type II • Mucopolysaccharidosis Type IV A • Mucopolysaccharidosis Type VI • Others By Route of Administration • Intravenous • Intracerebroventricular By End User • Hospitals • Specialty Clinics • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is classified into treatment, disease type, route of administration, end user and region. The treatment segment is divided into enzyme replacement therapy and others. The enzyme replacement therapy is the primary treatment for MPS disorders, and they aim at replacing or generating the enzymes that are missing in the body, which is the primary reason for causing MPS. ERTs are the only approves therapeutics for MPS like for instance, MPS type II treatment has two therapeutics options, Hunterase and Elaprase, both of which are enzyme replacement therapies. Such a monopoly shall let this segment dominate the market during the forecast period. Other treatments such as hematopoietic stem cell transplants are under clinical trials which once approved, shall increase its demand amongst patients, thereby boosting its growth during the forecast period. The disease type segment is categorised into mucopolysaccharidosis type I, mucopolysaccharidosis type II, mucopolysaccharidosis IV A, mucopolysaccharidosis VI and others. The mucopolysaccharidosis type II or Hunter syndrome, is predicted to lead the market growth during the forecast period owing to the rising number of MPS type II patients across the world along with the availability of Elaprase and Hunterase. The route of administration segment is fragmented into intravenous and intracerebroventricular. The intravenous segment is predicted to hold the mucopolysaccharidosis market share as MPS therapies like Elaprase are administered with the help of intravenous injections. The end user segment is bifurcated into specialty clinics, hospitals and others. The hospitals segment is poised to dominate the market, and this can be credited to the availability of trained healthcare professionals who can administer these therapies in hospital settings.
Regional Analysis:
The North America region is expected to dominate the market owing to the increased rate of treatment of rare diseases and the higher rate of rare disease diagnosis in the region. Furthermore, there has been significant improvements in the reimbursement policies for these therapies couple with a rising awareness amongst patients regarding the treatment of MPS. Additionally, a strong presence of key market players in the region who are constantly looking for alternate cost-effective therapies which shall bolster the market domination.
Competitive Landscape:
Some of the key players are Shire (Takeda Pharmaceutical Co. Ltd.), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, Genzyme Corp.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global mucopolysaccharidosis market by treatment, by disease type, by route of administration, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Mucopolysaccharidosis Market, By Treatment Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Enzyme Replacement Therapy 7.2 Others 8. Mucopolysaccharidosis Market, By Disease Type Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 Mucopolysaccharidosis Type I 8.2 Mucopolysaccharidosis Type II 8.3 Mucopolysaccharidosis Type IV A 8.4 Mucopolysaccharidosis Type VI 8.5 Others 9. Mucopolysaccharidosis Market, By Route of Administration Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 9.1 Intravenous 9.2 Intracerebroventricular 10. Mucopolysaccharidosis Market, By End User Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 10.1 Hospitals 10.2 Specialty Clinics 10.3 Others 11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 11.2.1. U.S. 11.2.2. Canada 11.2.3. Mexico 11.2.4. Rest of North America 11.3 Market Size (USD Mn) Forecast for North America 2020-2027 12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Regional Market Trends 12.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 12.3.1. Brazil 12.3.2. Venezuela 12.3.3. Argentina 12.3.4. Rest of Latin America 12.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027 13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5 Switzerland 13.2.6. Spain 13.2.7. Russia 13.2.8. Poland 13.2.9. Rest of Western Europe 13.3 Market Size (US$ Mn) Forecast for Europe 2020-2027 14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 14.2.1 Japan 14.2.2 China 14.2.3 Singapore 14.2.4 Korea 14.2.5 India 14.2.6 Australia and New Zealand 14.2.7 ASEAN 14.2.8 Rest of Asia Pacific 14.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1 Introduction 15.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 15.2.1 UAE 15.2.2 South Africa 15.2.3 Egypt 15.2.4 Saudi Arabia 15.2.5 Rest of MEA 15.3 Market Size (US$ Mn) Forecast for MEA 2020-2027 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 16.1 Shire (Takeda Pharmaceutical Co. Ltd.) 16.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2 Denali Therapeutics 16.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3 ArmaGen 16.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4 REGENXBIO Inc. 16.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 Sangamo Therapeutics 16.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 BioMarin 16.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7 Lysogene 16.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8 Abeona Therapeutics Inc. 16.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9 Ultragenyx Pharmaceutical 16.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10 Genzyme Corp. 16.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 17. Impact of COVID-19 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the healthcare regulations initiated by administrations 17.5. The overall economic slowdown of the developing and developed nations 18. Competitive Intelligence and Competitive Matrix 18.1 Competitive Intelligence 18.2 Competitive Matrix 19. Major Deals and Strategic Alliances Analysis 19.1 Joint ventures 19.2 Mergers and acquisitions 19.3 Licensing and partnerships 19.4 Technology Collaborations 19.5 Strategic Divestments 19.6 Market Entry Strategies 20. Relevant Case Studies and Latest News Updates 21. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics